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Standardization of intravenous medication beyond use dating at a large health-system 
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Within a large, nine-hospital health-system, there are a number of hospitals that have 
historically reviewed the current literature individually to establish hospital-specific non-
hazardous compounded sterile product (CSP) beyond-use date (BUD) lists. Creating and 
standardizing the list on a system level is a potential model that could reduce work at the individual 
site level, increase network patient safety, and facilitate the implementation of network technology. 
Researchers reviewed the most up-to-date literature and current non-hazardous CSP BUD lists at 
each site for inconsistencies to highlight the value and increased safety associated with 
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Compounding medications is a key component to the practice of pharmacy. In the last one 
hundred years, commercial manufacturing of medications at a large scale became less common. 
Medications that are commercially available for purchase may not be compounded to protect the 
manufacturer’s patent on the product1. There is still a need for medications to be compounded 
especially in situations where the available formulation is unsuitable for the patient as well as for 
many compounded sterile products (CSPs) that would have short expiration dates if they were to 
be manufactured.  
As the role of hospital pharmacists was defined throughout the twentieth century, inpatient 
facilities began to rely more heavily on pharmacies to mix CSPs2,3. CSPs were historically mixed 
by the nursing team at the patient’s bedside, but this is recognized as a potential danger to patient 
safety1,3. CSPs are regulated by the Food, Drug, and Cosmetic Act (FDCA) which requires all 
medications to meet United States Pharmacopeia (USP) standards1. USP standards had existed as 
quality guides since 1820, but until this point, they were simply a best practice rather than a legal 
requirement1. As patient-specific compounding became more infrequent and quality standards for 
manufacturing became more stringent, the USP organization began to draft standards directed at 
compounding quality1,2,3. These were organized into three chapters: non-sterile (USP <795>), 
sterile (USP <797>), and hazardous (USP <800>). The scope of this project focuses specifically 
on products regulated under USP <797>. Hazardous products were excluded from the project and 
are a source for future quality improvement in the health system.  
USP <797> discusses the two components of how long a CSP can be used for: stability and 
sterility7. Stability is defined as “the extent to which a product retains, within specified limits and 
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throughout its period of storage and use, the same properties and characteristics that it possessed 
at the time of [compounding].” Stability is dependent on the medication and its chemical 
properties, medication concentration, the diluent, the container that the medication is stored in, 
exposure to light, and the storage temperature.  
Sterility is defined as “freedom from the presence of viable microorganisms.” Sterility is 
dependent on the storage temperature and level of risk associated with the compounding 
procedure. Risk is defined in USP <797> as either high, medium, or low. USP <797> specifically 
calls out sterility. Personnel and compliance with USP regulations can also affect the sterility of a 
product. Stability is often determined by the manufacturer or published stability studies. It is 
important to match and consider the other factors that could affect stability, such as concentration, 
diluent and container, when reviewing stability studies. A product’s beyond-use date (BUD) can 
be assigned by reviewing the stability from the available data and sterility dictated by USP <797> 
and choosing the time that is the most conservative.  
 




(20 – 25°C) 
Refrigerator 
(2 – 8°C) 
Freezer 
(-25 – -10°C) 
Low Risk 48 hours 14 days 45 days 
Medium Risk 30 hours 9 days 45 days 





The variables and potential downfalls when compounding sterile products are numerous. 
With an increasing number of mergers and acquisitions creating large health-systems, 
standardizing different populations and practices is a challenge. There are a number of reasons 
why creating standard network beyond-use-dating resource for compounded sterile products is 
advantageous. Without standardization, sites likely have their own resource that are updated and 
validated at variable frequencies. One standard document owned at a health-network level is likely 
to save time across the network and prevent duplicative work. This standard document may lead 
to an increased level of patient safety by reducing errors due to lack of sterility or unstable 
medications administered to patients. Additionally, standardizing CSP practices such as BUD can 
facilitate the implementation of intravenous (IV) workflow technology. IV workflow technology 
has been shown to significantly decrease the number of medication errors as well as wasted and 
missing doses4,5. This decreases cost associated with wasted doses and increases patient safety. In 
2018, a survey of United States hospitals showed that only 16.4% of hospitals use sterile 
compounding technology and practices of how sterile products are tracked and maintained varied 
widely in the survey. This statistic showcases another barrier created when a merger or acquisition 
is conducted considering that new sites are likely to have different CSP practices6. While it is 
known that other hospitals and health-systems have a similar resource, it is not well documented 
how many health-systems have beyond use dating documents or use standard beyond use dating 
in their IV workflow solutions. The publication of the project aims to promote public health 
information sharing and encourage the use of standardized documents such as this one in the 
healthcare community. 
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This paper details a quality improvement project conducted at a nine-hospital health-
system in the north-eastern United States in an attempt to standardize the CSP BUDs across the 
network. The health-system has undergone several mergers and acquisitions throughout the last 
two decades. Historically, each hospital has managed their CSP beyond-use dating at the site-level. 
The manager at each site is then responsible for implementing any changes and educating staff. 
Currently, only one of the nine hospitals, the flagship hospital, utilizes IV workflow technology 
for compounding. Seven of the hospitals use a tracking system built into the electronic health 
record (EHR).  
The objective of this project is to standardize the beyond-use-dating of non-hazardous 
CSPs throughout a nine-hospital health-system in preparation for the implementation of IV 
workflow technology. Several secondary objectives were also explored during this project. The 
researchers sought to capture the number of discrepancies between the CSP BUD lists and the 
current literature, develop a standardized process to maintain accuracy of the list over time, and 
implement the list into IV workflow technology. It is hypothesized that creating and standardizing 
the list on a health-system level is a potential model that could reduce work on the level of the 
individual site and facilitate the implementation of IV workflow technology in the near future. 
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2.0 Methods 
The assembled research team consists of one site-lead from each of the nine hospitals. Each 
site-lead provided their CSP BUD resource(s) to the primary researcher. The CSP BUD list from 
the flagship hospital would be used as the template and information from other hospitals was added 
or amended using the existing structure. The primary researcher reviewed the medications listed 
to ensure that they are in-line with the current literature with clear source citations (Figure 1). 
 
 
Figure 1 Research Methodology 
 
Stability data is analyzed first by looking at the information provided in the product’s 
package insert and Lexicomp. If stability could be obtained and validated using both sources, the 
researchers did not proceed with a more detailed investigation of stability and proceeded to the 
third step in Figure 1. If the sources do not match or one or both of those resources is incomplete, 
other tertiary resources are explored until two sources confirmed the medication’s stability. If this 
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cannot be achieved through review of available tertiary resources, a database search is run with to 
consider primary literature exploring stability information. The key words used in this data base 
search is the name of the medication, “IV,” and “stability.” Once the stability is established, 
sterility is determined using USP <797> guidance. Many medications at these hospitals are made 
in batches, so the researchers assumed that all compounding is at the medium risk level. If sterility 
is shorter than stability, the sterility would dictate the BUD. If stability is shorter than sterility, the 
stability would dictate the BUD.   
Discrepancies are tracked to show the value of standardization. Then, the researcher 
compares the resources with one another, adds missing medications, and compiles an up-to-date 
list of medications, their concentrations, and their sterility and stability. This tool returns to the 
site-leads for review, suggestions, and updates until a final product is approved. The site-leads are 
responsible for rolling out the product at their site. The primary researcher is responsible for an 
update at the decided upon frequency and would work with the site-leads to create a process of 
updating the resource at the decided upon interval and as needed in the future. The team did not 
perform any advanced statistical analysis.  
Several adjustments to the original methods were made during the project. First, the team 
removed all stability on the chart for premixes removed from foil packing and stability secondary 
to medication container systems such as Mini-bag Plus or Vial-mate. This information was initially 
included because these items are processed in the pharmacy workflow in a similar way to CSP, 
but these items are not CSPs and have generic beyond-use-dating. Next, primary literature is used 
several times when multiple tertiary sources confirmed shorter stability. All primary literature that 
supersedes multiple tertiary databases is peer reviewed literature, and studied the CSP under the 
same conditions that the health-system uses (same diluent, concentration, container, temperature 
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etc.). Extended-stability studies became more useful and advantageous than initially anticipated 
by the team, and several sites had this literature readily available, and it is utilized to justify 
extending the CSP’s BUD. These changes to the methodology are detailed as key lessons learned 
throughout the discussion.  
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3.0 Results 
Six of the nine hospitals in the health-system had an available BUD and concentration 
resource prior to the beginning of the project.  Three of the hospitals report no resource prior to 
this project and confirmed that stability and sterility information is researched each time a 
medication is compounded. 352 unique CSPs were reviewed. 10% of the CSPs reviewed (35 
medications) showed updated stability information since the last review. One hospital’s resource 
had been updated within the last calendar year, more recently than other hospitals’ resources, and 
of the 50 CSPs on the hospital’s list, 2 of those medications required updates to their stability.  
In November 2020, the health-system established version one of the standard network 
resource. The site-leads noted many differences from their previous CSP BUD resources, and work 
on a second version of the document began shortly after implementation. 
Table 2 Version One to Version Two Key Changes 
Medication Version One Version Two 
Dexmedetomidine 24 hours refrigerated 9 days refrigerated 
FEIBA 
Not included Included 
Medication container 
system stability  
Included Not included 
Morphine 30 hours room 
temperature 
Option for 9 days 
refrigerated as well 
Octreotide 24 hours refrigerated 30 hours room 
temperature 
Protect from light 
(PFL) medications 
Listed in the comment 
section 
Listed in a separate 
column; also added 
columns to denote high 
alert medications and 
medications that 
require a filter 
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Revisions include CSPs compounded infrequently or compounded outside of the EHR that 
were not included on the list or extended-stability data. The group begans revisions to create a 
second version of the network resource in December 2020 and the second version was finalized in 
April 2021. This revision included the addition of three columns: protect from light, high alert, 
and filter to alert the user of additional stickers or post-preparation instructions; this is counted as 
one change although it affected many of the medications. The version also removed all stability 
secondary to medication container systems such as such as Mini-bag Plus or Vial-mate; this is 
counted as one change although it affected many of the medications. 41 total changes were made 
to the document between version one and version two; some important examples are highlighted 
in Table 2. This final list was provided to the new network IV workflow technology system for a 




This project led to many benefits such as information sharing among sites, ease of 
technology implementation, and it is believed, but not proven, that the project also created 
increased patient safety and cost savings in the network. The project succeeded largely because 
the team was nimble enough to respond to challenges and embrace lessons learned.  
Sites within the network had site-leads compiling their lists with a variety of experience 
with USP regulation and CSPs. The comprehensiveness of each site’s list varied greatly, and some 
of the initially collected resources referenced a combination of extended stability and manufacturer 
stability data as well as just sterility data. The group took longer than anticipated to agree on the 
structure of the document. Each hospital provides a different perspective, and the expectations of 
what the final product would like varied. This could have been anticipated considering that there 
are many variables that must be considered when assigning a BUD and could be broken down 
further to consider the components that factor into choosing appropriate sterility and stability 
information. There were moments where the project experienced scope creep in an attempt to 
accommodate all site needs in one comprehensive document. This quickly became unrealistic and 
less user-friendly for the primary user of the document, technicians compounding in the buffer 
room. This had was mitigated by a phone call with all group members to discuss perspectives and 
expectations until a consensus was reached. The team kept some of the information utilizing the 
“hide” feature in Microsoft Excel to maintain information in the electronic copy maintaining a 
user-friendly resource that accommodates the variety of practices and populations around the 
network. 
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In addition to the many lessons learned coordinating the project, several adjustments were 
made to the original strategy to improve the final product as briefly discussed above. The 
medication container system beyond-use dating and premix stability out of the foil packaging is 
now excluded after discussion. The researchers agreed that these products are not CSPs and the 
end-user friendliness would be greatly increased with the removal of these items. The intention 
behind relying on tertiary data sources as the preferred source of data is ease of standardization as 
well as updating and validating the information. The addition of primary literature to displace 
tertiary literature seems logical, but it presented more variables and required a deeper 
understanding of the principles behind medication stability. Extended-stability studies became 
more useful and advantageous than initially anticipated by the team, and several sites had this 
literature readily available and used it to justify extending the CSP’s BUD. These extended-
stability studies also lead to more medication that were able to be assigned longer beyond-use 
dates. Several medications were also indicated low risk compounds rather than medium risk if they 
are always compounded for a specific patient one dose at a time and the stability data would allow 
for a longer BUD if the medication were compounded under low risk conditions. These two 
nuances allowed several medications to be assigned longer BUDs than the health-system 
historically assigned. 
This project likely results in overall departmental efficiency and soft-dollar cost savings 
that, while challenging to quantify, are crucial to consider. One cost-saving mechanism across the 
network is through the reduction of the burden on the site-level leads when compiling the beyond-
use-dating list. Pharmacy management salaries are large expenses for inpatient pharmacies 
considering that the average hospital operates with tight financial margins; leveraging their time 
in the most efficient and cost-effective is preferred. This project removes the burden of updating 
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and validating this list annually and remove the step of concentration and BUD standardization 
when implementing the network IV workflow technology. The sites also worked together in the 
draft process to obtain the best stability data each location had access to, which increased the BUD 
on many medications. When a medication is compounded but not given to the patient, there is 
opportunity for the dose to be reused if an identical compound is needed for another patient within 
the BUD. This naturally becomes more likely when the BUD is longer. When this concept is 
extrapolated across all nine hospitals within the health-system, there is likely to be cost-savings 
associated with decreased waste. The cost of medication waste is not and was not being captured 
prior to the project and is unfortunately unavailable for formal analysis.    
Standardization of IV medication BUDs promotes larger public health goals. This project 
leads to a higher level of standardization and creates safer environments for patients. When patients 
enter a health care facility, they expect to have knowledgeable clinicians taking care of them and 
receive a high level of care. Deviations from this expectation are, at the very least, frustrating for 
patients and may cause patient harm. Generally, standardization in the health care leads to fewer 
deviations in data-driven, best-practices. Patient harm due to health care issues is an epidemic of 
great scale. Medical mistakes are the third leading cause of death in the United States8. Rates of 
errors in IV compounds is estimated to be nearly 9%8. Standard concentrations and beyond-use 
dating has been adopted and studies at organizations across the country as an error reducing 
strategy9. The prevalence of administration of unstable or contaminated medications is largely 
unstudied and extremely challenging to capture. Errors caused by beyond use date errors or 
inaccuracies are likely to be underreported and generally challenging to capture considering that 
patients who are taking IV medications in the hospital setting typically present with a complicated, 
multifactorial, clinical pictures which muddies the waters of underlying causes. Even if this were 
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examined more closely, it is unlikely to lead to significant differences in errors due to low reporting 
and the challenge associated with realizing this error caused patient harm. Though it is challenging 
to capture, prevention of patient harm due to medication instability or lack of sterility may result 
from this project. This error prevention is an important public health outcome of this project but is 
not likely to be quantifiable at a single health-system level.  
While obtaining data on error prevention rate is unlikely to be quantifiable, cost savings to 
the health-system and health care cost savings generally may result from this project. Using the 
best stability information available and recognized by hospitals in the health-system allows more 
time to use or reuse an IV product after compounding. This leads to less waste and reduces health 
care spend overall. Some of the hospitals in the health-system compound infrequently and did not 
historically have this information readily available to them. Historically, each medication that was 
compounded was either researched or assigned a conservative BUD. The time spent researching 
the beyond use dating reduces departmental efficiency and creates a cost burden on the department. 
Additionally, this practice takes time, emphasis, and focus away from the checking the validity of 
the compounded product. Adding this additional mentally taxing step could lead to missed errors 
and patient harm. Through information sharing and extended beyond use dating, it is likely that 
health care spend decreases; this would be a potential area for future studies to more closely 
consider as this would assist in quantifying the public health impact. 
Overall, the team found many of the anticipated benefits sat the conclusion of the project, 
but there are also many lessons learned. In the current health care climate, a focus on projects that 
benefit public health and create a high quality of care is crucial to modernizing health care 
practices. Publishing projects such as this one and sharing this information with other health care 
providers is key to promoting standardization and data-driven health care. The standardization of 
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this intravenous beyond-use dating list at hospitals across a health-system was a key quality 
improvement project that led to cost-savings, increased data-driven medication safety and overall, 
better patient care.
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Additional Comments  
Acetazolamide 
sodium  
Diluted in 50 mL NS 
12 hrs RT 
        
3 days REF 
Acetylcysteine  
6,000 mg/200 mL 
D5W 24 hrs RT 
      
  
12,000 mg/400 
mL       
30,000 
mg/1000mL        
Acyclovir  
Dilute in 100 mL 
to 250 mL - see 
comments  
D5W 24 hrs DNRF       
< 700mg diluted in 100ml 













3 hrs RT   x   
Administer within 3 hours 
 Filter during administration 
with a 5 to 15 micron filter  
Alteplase 
10 mg/50 mL 
NS 8 hrs DNRF         6 mg/120 mL 




24 hrs RT       
</= 500mg diluted in 
100ml 
16 
Dilute in 100 mL 
to 250 mL - see 
comments  
14 days* REF 
> 500mg diluted in 250ml 




1-5 g/100 mL NS 
48 hrs* RT     x 
*Assuming low risk 
compounding 25 g/250 mL D5W 
Aminophylline 




14 days* REF 
x     
Syringes for stress lab 
Supplied as vials containing 
25 mg/mL. 
Withdraw 2 mL (25 mg/mL) 
into a 20 mL syringe, 
further dilute with 8 mL 
bacteriostatic water for 
injection. 
Protect from light 
*Assuming low risk 
compounding 
50 mg/50 mL D5W 24 hrs RT 
Amiodarone 450 mg/250 mL D5W 24 hrs REF   x   
Use a DEHP free bag 
If using a glass bag; 24 




10 mg/100 mL 
D5W 
24 hrs RT 
X X   
Reconstitute with 
SWFIPeripheral line = 
0.1mg/mLCentral line = 
0.25mg/mLADULT</=25m
g diluted in 250ml26-50mg 
48 hrs REF 
50 mg/10 mL 
24 hrs RT 
48 hrs REF 
17 
Dilute in 250 to 
1,000 mL - see 
comments 
24 hrs RT 
diluted in 500ml> 50mg 
diluted in 1000ml 




Dilute in 250 or 
500 mL -  
see comments  
D5W 
6 hrs RT 
X     
Filter when adding to IV 
bag 
Do not use in-line filter 
Do not mix with saline 
containing solutions 
Begin administration within 
6 hours of compounding 
< 400mg diluted in 250ml 
>/= 400mg diluted in 
500ml 




40 mg/40 mL 
D5W 24 hrs REF   X   
Filter when adding to IV 
bag  
Do not mix with saline-
containing solutions  
200 mg/250 mL 
Ampicillin 
1 gm/50 mL  
NS 48 hrs REF       
Admixure 
Protect from freezing 
2 gm/100 mL  
18 
3000 mg/100 mL  24 hrs 
Ampicillin/ 
Sulbactam  
1.5 gm/50 mL  
NS 
8 hrs RT 
      Admixture 
48 hrs REF 
3 gm/100 mL  
8 hrs RT 




- NS 24 hrs RT   X x 
25mg vial should be diluted 
in 50mL Send with primed 
IV line with 0.22 micron 
inline-filter  
Argatroban  50 mg/50 mL NS 96 hrs REF X   x 
Admixure  
Protect from light 
Ascorbic Acid  1,500 mg/50 mL 
NS or 
D5W 
96 hrs REF X     Protect from light  
Azithromycin  500 mg/250 mL D5W 7 days REF       Admixure 
Aztreonam 
20 mg/50 mL 
NS 
24 hrs RT 
      Admixure 
12 mg/5 mL 48 hrs RT 
1 gm/50 mL  
48 hrs RT 
7 days REF 
2 gms/100 mL  
48 hrs RT 
7 days REF 
Basiliximab 20 mg/50 mL NS 
4 hrs RT 
      
Immediate use is 




D5W 24 hrs RT     x   
250 mg/50 mL 
Belatacept 




24 hrs REF   x   
Infusion must be completed 
within 24 hrs of 
reconstitution with a 
maximum of 4 hours of the 
24 hours at room 
temperature 
Send 0.2 to 1.2 micron low 
protein-binding filter 
Bumetanide 
10 mg/40 mL  - 
24 hrs DNRF x     
Protect from light 
Undiluted and admixed in 
empty e-vac bag UNLESS 
dose is greater than 4g 
(dilute with NS to achieve a 
total volume of 50 mL)  
Dilute dose in 50 
mL 
NS 
Bupivacaine 375mg/300mL NS 
48 hrs* RT 
      
For Epidural 
Not for IV Use 
*Assuming low risk 
compounding 
9 days  REF For Anesthesia only 
Caffeine citrate 60 mg / 3 mL D5W 24 hrs RT     x 
Stock vials should be 
discarded from the IV room 
every 8 hours. 
Calcitonin Injection n/a 
30 hrs RT 
      
Draw up weight based dose 
using the 200 units/1 mL 
product undiluted in a 
syringe  
Protect from freezing 
9 days REF 
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Calcium Chloride   Dilute in 100 mL 
NS or 
D5W 
24 hrs DNRF         
Calcium 
Gluconate  
Dilute in 100 mL 
NS or 
D5W 
24 hrs RT         
Cangrelor  50 mg/250 mL  NS 24 hrs RT       Avoid vigorous mixing 
Capsofungin 
Dilute dose in 250 
mL 
NS 
24 hrs RT 
      Admixture 
48 hrs REF 
Cefazolin  
Injection   
24 hrs RT 
      
  
10 days REF 
2 gm/50 mL  
D5W 
48 hrs*  RT 
Admixure 
*Assuming low risk 
compounding 
14 days* REF 
3 gm/100 mL  
48 hrs*  RT 
14 days* REF 
6 gm/250 mL  
48 hrs*  RT 
14 days* REF 
Cefepime 1 gm/100 mL  NS 
24 hrs RT 
      Admixure 
7 days REF 
21 
2 gm/100 mL  
24 hrs RT 
7 days REF 
Cefotaxime  




24 hrs RT 
        
5 days REF 
Cefotetan  
1 gm/50 mL  
D5W 96 hrs REF X     Protect from light 2 gm/50 mL  
Cefoxitin 




6 hrs RT 
        
7 days REF 
Ceftaroline Dilute in 100 mL NS 24 hrs REF       
Can be stored at room 
temperature for 6 hours if 
needed 
Ceftazidime 
Dilute dose in 50 
mL 
NS 3 days REF 
      
Admixture 




2.5 gms/100 mL 
NS or 
D5W 
12 hrs RT 
      Admixture 




1.5 gm/50 mL  NS 
24 hrs RT 
        
7 days REF 
Ceftriaxone 1 gm/50 mL NS 48 hrs RT 
22 
2 gms/50 mL*        
Doses greater than 2 g 
should be diluted in 100 mL 
Cefuroxime 




24 hrs RT 
X     Protect from light 7 days REF 
Chlorpromazine 25 mg/50 mL NS  24 hrs RT X     Protect from light  
Ciprofloxacin  
200 mg/100 mL D5W 30 hrs RT 
X     Protect from light 
400 mg/200 mL D5W 24 hrs REF 
Cisatracurium 100 mg/100 mL NS 24 hrs REF     x   
Clindamycin 
600 mg/50 mL 
D5W 
30 hrs RT 
        
9 days REF 
900 mg/50 mL 
30 hrs RT 
9 days REF 
Colistimethate 150 mg/100 mL NS 24 hrs RT         
Conivaptan 20 mg/100 mL  D5W 24 hrs RT         
Dalbavancin 
Dilute dose in 100 
- 250 mL - see 
comments 
D5W 48 hrs* RT       
</=500mg diluted in 
100ml 
>500mg diluted in 250ml 





Dilute dose in 250 
mL 
D5W 
5 hrs RT 
        




Dilute to maintain 
concentration 
SWFI 6 hrs RT X     Protect from light 
Daptomycin 
(Cubicin®)  
Dilute dose in 50 
mL 
NS 
12 hrs RT 
      
Refer to manufacturer 
specific beyond use dating 
- some products are stable 
for longer than this 




SWFI 24 hrs DNRF       
Manufacturer recommends 
use  within 3 hours of 
reconstitution 
Desmopressin  
Dilute dose in 50 
mL 
NS 24 hrs RT         
Dexamethasone 
Dilute dose in 50 




24 hrs RT X     
Protect from light 
Doses </=10mg may be 
given undiluted 
Doses >10mg diluted in 
50mL 
Dexmedetomidine 
20 mcg/5 mL 
NS 
9 days REF 
    x   
40 mcg/10 mL 
0.2 mg/50 mL  
48 hrs RT 
0.4 mg/100 mL 
Digoxin Immune 
fab 
Dilute in 50 mL NS 4 hrs REF   X   
Send with 0.22 micron filter  
Do not shake vials 
Diltiazem 
100 mg/100 mL  
D5W 24 hrs RT         125 mg/125 mL 
Diphenydramine 
50 mg / 1 mL  -  30 hrs RT 
X     
Protect from light 
*Assuming low risk 
compounding 
Dilute dose in 50 
mL 
NS 14 days* REF 
24 
Dobutamine 500 mg/250 mL D5W 
24 hrs RT 
    x   
48 hrs REF 
Dopamine 400 mg/250 mL D5W 36 hrs RT X   x Protect from light 
Dornase alfa 5 mg/30 mL NS 24 hrs REF X     
Protect from light 
Do not expose to room 









30 days RT 
X     Protect from light 72 hrs REF 
Eculizumab 
900 mg / 180 mL 
NS 24 hrs RT     x   1200 / 240 mL 
Epinephrine  




REF x   x 
Protect from light 
10 mg/250 mL  9 days Protect from light 
High concentration sticker 
Ertapenem 
Dilute dose in 50 
mL 
NS 
4 hrs RT 
  
    
Admixure 
24 hrs REF     
Erythromycin 
lactobionate 
Dilute dose in 
100-250 mL - see 
comments 
NS 24 hrs REF       
Reconstitute vial with SWFI 
</= 250mg diluted in 
100ml> 250mg diuted in 
250ml 
Ethacrynic Acid 
Dilute dose to 
achieve 
NS 24 hrs RT         
25 
concentration of 1 
mg/1 mL 
Famotidine 
10 mg/ 10 mL 
NS 48 hrs REF 
      
  
20 mg / 50 mL       




4 hrs RT       
  
24 hrs REF       
Fentanyl 
See Epic Standard 
Concentrations 
NS 30 hrs RT x   x 




Undiluted  -  
30 hrs RT       
Concentration must always 
be greater than or equal to 
2 mg/mL 




100 mg/50 mL  
NS 
24 hrs 
RT       
Expiration date applies 
when Premix bag is split 
into multiple doses  600 mg/300 mL 
24 hrs 
800 mg/400 mL 
Folic Acid  
1 mg/0.2 mL - 
24 hrs RT X     
Protect from light 
Undiluted 
1 mg/50 mL NS 
Fomepizole 
1,600 mg/100 mL 
D5W 24 hrs RT         2,400 mg/100 mL 
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Fosaprepitant 
150 mg/150 mL 
NS 24 hrs RT         150 mg/250 mL 
Foscarnet  




NS 24 hrs RT         
Fosphenytoin 
Dilute dose in 50-




48 hrs*  RT 
      
</=200mg may be given 
undiluted  
>200mg to 749mg diluted 
in 50ml 
>/= 750mg diluted in 
100ml 
*Assuming low risk 
compounding 
14 days* REF 
Furosemide   
Dilute dose in 50 
mL - see 
comments NS 24 hrs RT x     
</= 160mg may be 
undiluted>160mg diluted in 
50ml 
300 mg/100 mL 
Protect from light 
High concentration sticker 
Gentamicin 
Dilute dose in 50 - 
250 mL - see 
comments 
NS 48 hrs*  RT       
Admixure 
Expiration date is the same 
at RT and REF 
</=100mg diluted in 50ml 
> 100mg to 250mg diluted 
in 100ml 
> 250mg diluted in 250ml 
*Assuming low risk 
compounding 
Glucagon  10 mg/100 mL D5W 24 hrs RT x     
Protect from light 
For immediate use  
1 mg = 1 unit  
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Heparin  
500 units/500 mL NS 
24 hrs 
RT  








Hydrocortisone  100 mg/100 mL NS 48 hrs*  RT x     
Protect from light  
*Assuming low risk 
compounding 
Hydromorphone 
Dilute dose in 50 
to 250 mL 
NS 
30 hrs RT 
x   x Protect from light 9 days REF 
Hydroxocobalami
n 
5 g/200 mL NS 6 hrs DNRF       Do not shake  
Ibutilide 




24 hrs RT 
      
Note that the medication is 
more stable at RT 48 hrs REF 
Imipenem/ 
Cilastatin 
500 mg/100 mL* NS 
4 hrs RT 
      
*Doses greater than 500 
mg should be diluted in 250 




- D5W 24 hrs RT       
Send with tubing 
Do not shake  
Infliximab Dilute in 250 mL NS 5 hrs** RT   X   
**Start infusion within 3 
hours of preparation 
Send with 1.2 micron (or 
smaller) filter 
Insulin, regular 100 units/100 mL NS 14 days* REF     x 
Expiration date for insulin 
used for IV infusion 
*Assuming low risk 
compounding 
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Insulin U-500 500 units/100 mL NS 
24 hrs RT 
    x 
Undiluted in a syringe - 
High concentration sticker 
Date when vial is 
opened and expiring  
*Assuming low risk 
compounding 
14 days* REF 
Iron Dextran  
25 mg/0.5 mL 
NS 24 hrs RT         
100 mg/2 mL 
Dilute dose in 500 
mL 
Iron Sucrose 
Dilute dose in 250 
mL 
NS 7 days REF        
</=200mg given undiluted 





24 hrs REF x     Protect from light  1mg/250mL 
1 mg/500mL 
Kcentra n/a SWFI 8 hrs RT x     Protect from light 
Ketamine  
500 mg/500 mL  
NS 24 hrs RT x   x 
Protect from light 
1,000 mg/500 mL 
Protect from light 
High concentration sticker 
Labetalol   500 mg/100 mL  
Undilut
ed 
24 hrs RT x   x 
Protect from light  
Expiration date is the same 
at RT and REF 
Lacosamide 
Dilute dose in 100 
mL 
NS 24 hrs DNRF         
Leucovorin 
25 mg/50 mL Bacterio
static 
water 
30 hrs RT x     
Protect from lightSolutions 
reconstituted with SWFI 
must be used immediately 50 mg/50 mL 
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200 mg/50 mL 
Levetiracetam  
Dilute dose in 100 
mL 
NS 24 hrs DNRF       
Refer to manufacturer 
specific beyond use dating 
- stability is formulation 
depedent 
Levocarnitine 
Dilute dose in 250 
mL 
NS 24 hrs RT         
Levofloxacin 250 mg/50 mL D5W 24 hrs RT x     Protect from light 
Levothyroxine 
- NS 7 days  REF 
x     
Protect from light 
Syringes 
200mcg/500ml NS 18 hrs RT 
Protect from light 
For organ harvest 
Lidocaine  2 gms/250 mL D5W 30 hrs RT         
Lorazepam  
40 mg/250 mL 
D5W 24 hrs DNRF x x   
Protect from light 
Use a DEHP-free bag  
Send with 0.22 micron filter 
160 mg/40 mL High concentration sticker 
Magnesium 
Sulfate  
Dilute dose in 50 - 
1,000 mLs* 
NS 30 hrs DNRF     x 
Admixture  
1-4 grams diluted in 50-
1,000 mLs depending on 
order 
Meropenem  
500 mg/50 mL  
NS 15 hrs REF       Admixure 1 gm/100 mL 
2 gms/100 mL  
Mesna 1 gm/10 mL 
NS or 
D5W 
24 hrs RT       




Dilute dose in 250 
mL 
NS 30 hrs DNRF         
Methyldopate 
Dilute dose in 100 
- 250 mL - see 
comments 
D5W 24 hrs RT       
</= 125mg diluted in 
100ml 
>125 mg diluted in 250ml 
Methylene Blue 
(Provay Blue) 
Dilute dose in 100 
mL 
D5W 1 hr* RT x     
Protect from light  





250 mg/100 mL 
NS 30 hrs RT x     Protect from light 500 mg/100 mL 
750 mg/250 mL 
Metoclopramide 
10 mg/2 mL 
NS 48 hrs* DNRF x     
Protect from light 
</= 10mg may be given 
undiluted 
>10mg diluted in 50ml 
*Assuming low risk 
compounding 




5 mg/50 mL D5W 36 hrs* DNRF       
*Assuming low risk 
compounding 
Metronidazole  
250 mg/50 mL 
NS 
48 hrs* 
RT       
*Assuming low risk 
compounding 500 mg/100 mL  48 hrs* 
Micafungin 




24 hrs RT x     
Protect from light  
Admixture 
Midazolam  50 mg/50 mL D5W 
30 hrs RT 
    x   
9 days REF 
Milrinone  20 mg/100 mL    30 hrs* RT     x 
Admixture 
*Assuming low risk 
compounding 
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Minocycline 100 mg/250 mL 
NS or 
D5W 
4 hrs RT 
      Admixture 24 hrs REF 
Morphine 




30 hrs RT 
x   x Protect from light 
9 days REF 
Multivitamin 
Infusion  




24 hrs RT x     Protect from light 
Nafcillin  Dilute in 500 mL D5W 7 days  REF       Admixture 
Naloxone 2 mg/500 mL  NS 24 hrs RT x   x Protect from light 
Nicardipine  
50 mg/100 mL 
NS 24 hrs RT x   x 
Protect from light 
High concentration sticker 
25 mg/250 mL  Protect from light 
Nitroglycerin  100 mg/250 mL D5W 
48 hrs RT 
x   x Protect from light 
7 days  REF 
Nitroprusside  50 mg/250 mL D5W 24 hrs RT x   x 
Protect from light  
Expiration date is the same 
at ART and REF 
Norepinephrine 
4 mg/250 mL  D5W 9 days  
REF X   x 
Admixure 
Protect from light  
16 mg/250 mL D5W 24 hrs 
4 mg/250 mL  NS 7 days  
16 mg/250 mL NS 24 hrs 
Octreotide   
250 mcg/50 mL 
NS 30 hrs RT x   x Protect from light 500 mcg/100mL 
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Ondansetron 




48 hrs* RT x     
Protect from light 
8 mg or fewer may be 
given undiluted 
*Assuming low risk 
compounding 
Oxacillin 
Dilute dose in 50 
mL 
NS 6 hrs RT       Admixture 
Oxytocin 30units/500mL NS 
30 hrs RT 
x   x Protect from light 
7 days REF 
Palifermin   5 mg/mL NS 1 hr* RT x     Protect from light 
Pamidronate  
60 mg/250 mL 
NS 24 hrs RT         
90 mg/250 mL 
30 mg/500 mL 
60 mg/500 mL 
90 mg/500 mL 
Pantoprazole  80 mg/250 mL NS 
24 hrs RT 
        
9 days REF 
Penicillin G 
Potassium  
4 million units/50 
mL 
D5W 7 days REF       Admixure 
10 million 
units/250 mL  
12 million 
units/250 mL  
Pentamidine 
Dilute dose in 50 
mL 
D5W 24 hrs DNRF x     Protect from light 
Pentobarbital 500 mg/ 100 mL NS 24 hrs RT     x   
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Peramivir 




24 hrs RT         
Phenobarbital  
Dilute dose in 100 
mL 
NS 24 hrs DNRF x     Protect from light 
Phenylephrine  Dilute in 250 mL 
NS or 
D5W 
4 hrs RT 
    x 
High concentration sticker 
if needed 9 days REF 
Phenytoin  
Dilute dose in 100 
mL 
NS 4 hrs DNRF x x   
Protect from light 
Send with 0.22 filter  
</=200mg may be given 
undiluted 
> 200mg diluted in 100ml 
Phytonadione  
Dilute dose in 50 
mL 
NS 24 hrs RT x     Protect from light 
Piperacillin/ 
Tazobactam   
2.25 gm/50 mL  
NS 24 hrs RT         3.375 gm/100 mL 
4.5 gm/100 mL  




12 hrs RT         
Polymyxin B 
Dilute dose in 100 
mL 
D5W 72 hrs REF x     Protect from light 
Posaconazole 300 mg/250 mL 
NS or 
D5W 
24 hrs REF         
Potassium 
chloride 




24 hrs RT     x 
Admixture 
Always use premix if 
availible 
Do not exceed a 




Dilute dose in 250 
mL 
NS 48 hrs* RT     x   
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Procainamide  
2 gm/500 mL  
NS 24 hrs RT         Dilute dose in 50 
mL 
Promethazine 
Dilute dose in 50 
mL 




500 units/20 mL 
SWFI 4 hrs RT x     
Protect from light 
Actual potency varies vial 
to vial  
1000 units/40 mL 
Rasburicase 
1.5 mg/50 mL 
NS 24 hrs REF x     Protect from light 3 mg/50 mL 
Ravulizumab 
Dilute dose in 50 
mL 
NS 
6 hrs RT 
x x   
Protect from light 
Send with 0.2 or 0.22 
micron filter 24 hrs REF 
Remdesivir 
Dilute dose in 250 
mL 
NS 
24 hrs RT 
        48 hrs REF 
Remifentanyl 
1 mg/20mL NS or 
D5W 
24 hrs RT         
2 mg/40 mL 
Rifampin  Dilute in 100 mL NS 30 hrs RT x     Protect from light 
Rocuronium 100 mg/100 mL NS  24 hrs RT         
Ropivacaine 2.5 mg/250 mL NS 24 hrs RT     x   
Sargramostim 250 mcg/mL SWFI 6 hrs RT         
Sodium 
Bicarbonate  













125 mg/250 mL  NS 24 hrs RT         
Sodium 
Phosphate 
Dilute dose in 250 
mL 
NS 24 hrs RT         
Sodium  
thiosulfate 
25 g/200 mL 
NS or 
D5W 
48 hrs* RT       
*Assuming low risk 
compounding 
Streptomycin 
Dilute dose in 100 
mL 
D5W 24 hrs RT x     
Protect from light 
Some manufacturers show 





Dilute dose in 100 
mL 
NS 12 hrs RT x     Protect from light 
Tenecteplase n/a SWFI 8 hrs REF         
Thiamine 
Dilute dose in 100 
mL 
NS 24 hrs RT         
Tigecycline 50 mg/100 mL NS 
24 hrs RT       
Admixture 
48 hrs REF       
Tobramycin 
Dilute dose in 100 
mL 
NS 48 hrs* RT       *Assuming low risk 
compounding 
D5W 24 hrs RT       
Tocilizumab 
Diliute dose in 100 
mL 
NS 24 hrs RT x x   
Protect from light 
Send with 0.22 micron filter 
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Tranexamic Acid 1000 mg/100 mL NS 48 hrs* RT       






48 hrs* RT       
Check for opened vials 
in the IV room 
Flolan diluent found in 
central pharmacy 




80 mg/125 mL 
D5W 
6 hrs 
RT       
For 6 hr stabilty, every 80 
mg of trimethoprim 
requires 125 mL of D5W 
 
For 4 hr stability, every 80 
mg of trimetheprim 
requires 100 mL of D5W 
160 mg/250 mL 
200 mg/250 mL 
4 hrs 
320 mg/400 mL 
400 mg/500 mL 
480 mg/600 mL 
Valproate 
Dilute dose in 100 
mL  
D5W 24 hrs DNRF         
Vancomycin 
500 mg/ 100 mL 
NS/D5
W 
9 days  REF       
Concentration to be  
≤5 mg/mL 
750 mg/250 mL 
1 gm/250 mL  
1250 mg/250 mL  
1500 mg/300 mL 
1750 mg/500 mL 
Vasopressin  20 units/50 mL  
NS/D5
W 
24 hrs REF     x   
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20 units/100 mL 
Vecuronium  50 mg/50 mL 
NS/D5
W 
24 hrs REF     x   
Vedolizumab 300 mg/250 mL NS 
12 hrs RT 
        
24 hrs REF 
Verapamil 40 mg/250 mL NS 24 hrs RT x     Protect from light 
Voriconazole  
Dilute dose in 100 
- 250 mL - see 
comments 
NS 24 hrs REF       
<500mg diluted in 100ml 
>/= 500mg diluted in 
250ml 
Zidovudine 400 mg/100 mL D5W 
8 hrs RT 
        
24 hrs REF 
Zoledronic acid 
4 mg/100 mL 
NS 24 hrs REF         






1. From guesswork to standards: The history of medicine quality | USP. (2020). United States 
Pharmacopeia.  
2. Brown TR. Handbook of Institutional Pharmacy Practice. Bethesda, MD: American 
Society of Hospital Pharmacists; 2006.  
3. Urick BY, Meggs EV. Towards a Greater Professional Standing: Evolution of Pharmacy 
Practice and Education, 1920–2020. Pharmacy. 2019;7(3):98. doi:10.3390/pharmacy 
7030098  
4. Deng, Y., Lin, A. C., Hingl, J., Huang, G., Altaye, M., Maynard, H., Mayhaus, D., & Penm, 
J. (2016). Risk factors for i.v. compounding errors when using an automated workflow 
management system. American Journal of Health-System Pharmacy, 73(12), 887–893. 
https://doi.org/10.2146/ajhp150278 
5. Lin, A. C., Deng, Y., Thaibah, H., Hingl, J., Penm, J., Ivey, M. F., & Thomas, M. (2018). 
The impact of using an intravenous workflow management system (IVWMS) on cost and 
patient safety. International Journal of Medical Informatics, 115, 73–79. 
https://doi.org/10.1016/j.ijmedinf.2018.04.004 
6. Pedersen, C. A., Schneider, P. J., Ganio, M. C., & Scheckelhoff, D. J. (2019). ASHP 
national survey of pharmacy practice in hospital settings: Monitoring and patient 
education—2018. American Journal of Health-System Pharmacy, 76(14), 1038–1058. 
https://doi.org/10.1093/ajhp/zxz099 
7.  United States Pharmacopeia and National Formulary (USP 797-NF 36). United States 
Pharmacopeial Convention; 2016.  
8. Deng Y, Lin AC, Hingl J, et al. Risk factors for i.v. compounding errors when using an 
automated workflow management system. Am J Health Syst Pharm. 2016;73(12):887-
893. 
9. Leigh Briscoe-Dwyer, Dan Degnan et al. Standardize 4 Safety: Guiding principles, 
decision matrix, and other considerations. American Society of Health-System 
Pharmacists. 2016 
